ARNA could start to become quite interesting play on the run up to the NDA, The FDA has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application. The shares are trading up pre market on a small volume of 43,000 trading up $0.18 cents from close last night of $3.05. With a trading range of $2.70 low to a high of $5.93 in September. We could see a nice substantial run up to the FDA date, ARNA is trading of its recent lows, If I was a buyer I would be waiting for a possible retraction in price.

About Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Our most advanced drug candidate is lorcaserin for weight management, which has completed a pivotal Phase 3 clinical trial program. In December 2009, we submitted a New Drug Application for lorcaserin to the FDA for regulatory approval, and the FDA has assigned an October 22, 2010, PDUFA date for the review of our application.

Arena website

http://www.arenapharm.com/wt/page/home.html

Investor Relations
Cindy McGee
IR and Corporate Communications
858.453.7200, ext. 1479

Pennystockspicksus has recived no compensated for this feature,

ARNA removed form feature. Congrats to the players who bought in on the feature call @ $2.80 or lower you would have made a solid gain of $4.50 profit at the peak.